Metformin, Statins Do Not Reduce Incidence of Ovarian Cancer in Women with Type 2 Diabetes, Study Says

Metformin, Statins Do Not Reduce Incidence of Ovarian Cancer in Women with Type 2 Diabetes, Study Says
Women with type 2 diabetes taking metformin or statins are not less likely to develop epithelial ovarian cancer than any other type 2 diabetes patient, a large Finnish cohort study reports. The study, "The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study," was published in BJOG: an international journal of obstetrics and gynaecology. People with type 2 diabetes are thought to also have increased risk of developing different cancers.  This could, in part, be due to increased body weight that often accompanies diabetes. A recent analysis showed increasing body weight in premenopausal women was associated with increased risk for developing ovarian cancer. Although the risk for developing cancer among diabetics is highest for those taking insulin, some studies suggest there may also be an association between cancer risk and other anti-diabetic drugs, such as metformin or statins. Metformin is an oral, anti-diabetic medication that is often prescribed as the first-line treatment for patients with type 2 diabetes. But it also has anti-tumor effects and some studies have suggested that metformin use is linked to lower incidence of different cancers. Statins are lipid-lowering drugs primarily used to treat cardiovascular disease in type 2 diabetes patients. Because people with type 2 diabetes have an increased risk of cardiovascular disease, patients are often treated with statins. Bu
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *